Semaglutide

Human evidence can mean a controlled clinical study, an observational study, a safety or exposure report, or evidence from a particular finished formulation. Those are different kinds of information.

More extensive human evidence in specific contexts. Human studies and labelled product evidence are available in specific contexts. This is not a ranking of suitability or a guarantee that every product or use has the same evidence.

Preclinical means research in cells, tissues, or animals rather than in people. It can help researchers form a hypothesis, but it cannot establish a human benefit or a complete human safety profile.

Nonclinical pharmacology and toxicology informed development, including rodent thyroid C-cell findings described in labeling. Animal findings do not determine an individual human outcome.[1]

Preclinical findings do not establish outcomes in people.

Risk information may describe the compound, a finished product, a route, a population, or product-quality concerns. The cited material does not replace a current product label or an individual professional assessment.

This section is about the United States only. Status applies to a product, formulation, route, population, and use—not to a name in the abstract. A status shown here is not a recommendation or a statement about another country.

• Source/status dateJun 30, 2026

  FDA-approved medicine

  Semaglutide is the active ingredient in multiple FDA-approved prescription products. Approval applies to the labeled product, formulation, route, population, and indication, not to every product sold as semaglutide.

  Specific product form or route is not separately published in this status record.

  Open source context

The date above is the date attached to the published status record or source context. It is not necessarily the original approval date.

These prompts help organise a conversation with a qualified professional. They do not create a treatment recommendation, dose, or protocol.

• EvidenceWhich human evidence applies to the exact product, form, route, and use being discussed?
• What remains uncertainWhat is known, and what remains uncertain for this specific context?
• RisksWhich important warnings, common effects, and product-quality concerns should be discussed?
• U.S. statusWhat does the U.S. status cover, and what does it not cover?

Related means that the profiles share a topic, pathway, product context, or research question. It does not mean that they are equivalent.

• TirzepatideBoth have FDA-approved metabolic and chronic weight-management products.
• LiraglutideBoth are GLP-1 receptor agonists with product-specific approvals.
• CagrilintideCagrilintide has been studied with semaglutide but remains investigational.

PeptideGrid review date: Jul 22, 2026. Sources support the specific sections that cite them. Publication does not imply endorsement, equivalence, or individual suitability.

1. 1

   WEGOVY prescribing information

   DailyMed. WEGOVY (semaglutide) prescribing information. Revised June 2026.

   National Library of Medicine / Novo Nordisk · Published Jun 30, 2026 · Accessed Jul 22, 2026 · Prescribing information

   Open source